Article

Daily Medication Pearl: Rivaroxaban (Xarelto)

Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis, and pulmonary embolism.

Medication Pearl of the Day: Rivaroxaban (Xarelto)

Indication: Rivaroxaban is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and of PE, and for the prophylaxis of DVT that may lead to PE in patients undergoing knee or hip replacement surgery.

Insight:

  • Dosing: Take 15 mg and 20 mg tablets with food. Take 10 mg tablets with or without food.
  • Dosage forms: Tablets 10 mg, 15 mg, and 20 mg.
  • Adverse events: The most common adverse reaction (>5%) was bleeding.
  • Mechanism of action: Rivaroxaban is a selective inhibitor of FXa. It does not require a cofactor (such as anti-thrombin III) for activity.
  • Manufacturer: Janssen Pharma

Sources:

  1. label (fda.gov)
  2. xarelto image - Google Search

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com